- Topical Hypertonic Agents
- Medications to Lower Intraocular Pressure
- Others
Bullous Keratopathy Market size was valued at USD 482 million in 2022 and is poised to grow at a CAGR of 7.2% over 2023-2029. Bullous Keratopathy, also known as pseudophakic bullous keratopathy, is a pathological condition in which small vesicles, or bullae are formed in the cornea due to endothelial dysfunction, resulting in swelling due to the excessive fluid and blisters on the cornea causing blurring of vision, caused by damage or inflammation due to eye surgery, trauma, and glaucoma. Based on the treatment type, amniotic membrane graft is anticipated to dominate the market share over the forecast period. Rising cases of cataract surgeries and the use of advanced technologies in corneal transplant and implant surgeries will act as the drivers for market growth. However, increased risk factors of the surgery with an increase in the risk of surgery failure will have a negative impact on the market. Favorable reimbursement policies and the need for research and development of new treatment methods are opportunities for the expansion of the market.
Bullous Keratopathy Market Key Developments:
- In Sep 2022, Celregen and Cellusion signed an exclusive license agreement for corneal endothelial cell regenerative therapy in Greater China.
- In Jul 2022, Carl Zeiss Meditec and Precise Bio announced a partnership in the development and commercialization of tissue-based implants for ophthalmology.
Bullous Keratopathy Market Summary
Study Period
2024-2030Base Year
2023CAGR
7.20%Largest Market
North AmericaFastest Growing Market
North AmericaBullous Keratopathy Market Dynamics
Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of bullous keratopathy. For instance, Corneat Vision, conducted clinical trials for their CorNeat Kpro (artificial cornea), which is likely to be commercialized in 2024. Additionally, Emmecell’s EO2002, a magnetic cell-based therapy, providing easier access to treatment before the disease becomes disabling and painful, is being evaluated in phase-I for surgery involving full-thickness corneal transplantation or endothelial keratoplasty. Thus, rising complications from cataract surgeries, glaucoma surgeries and the growing prevalence of eye disorders will lead to the growth of the market within the forecast period.
North-America Got Significant Share of
Bullous Keratopathy Market Regional Analysis
The Bullous Keratopathy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. As per the World Health Organization, globally, approximately 2.2 billion people had near or distant vision impairment and 4.2 million people had corneal opacities in 2020 According to an article published by Progress in Retinal and Eye Research in 2020, the late-onset form of Fuch’s endothelial dystrophy affected approximately 4% of people above 40 years of age in the USA. As per the National Eye Institute, an estimated 30,000 Americans undergo corneal transplants to replace injured and diseased corneas every year. The North America Bullous Keratopathy market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players, and the increasing research and development activities in the region. Also, in the European market the increasing research and development investments and practices focused on developing advanced corneal implants will create favorable expansion of the bullous keratopathy market.
Latin America
Europe
Asia Pacific
Middle East
North America
Bullous Keratopathy Market Segmentation
By Type
By Therapy
- Emmecell
- Cellulsion
By Treatment
- Lubricants
- Steroids
- Hyperosmotic Agents
- Anti-glaucoma Drugs
- Antibiotics
- Amniotic Membrane Graft
- Annular Keratotomy
- Anterior Stromal Puncture
By End User
- Hospitals
- Clinics
- Surgical Centers
- Others
Frequently Asked Questions
The Bullous Keratopathy market was valued at USD 482 million in 2022 and is expected to grow at a 7.2% CAGR over the forecast period 2023 – 2029.
Favorable reimbursement policies and the need for research and development of new treatment methods are the key opportunities for the Bullous Keratopathy market.
Rising cases of cataract surgeries and the use of advanced technologies in corneal transplant and implant surgeries are the growth drivers in the Bullous Keratopathy market.
Pfizer Inc, Roche Ltd., Regeneron Pharmaceuticals, Bayer AG, Cellusion, CRSTEurope, Barraquer Eye Hospital, Planchard Eye & Laser Center, and Medscape are a few companies operating in the Bullous Keratopathy market.
Key Features of the Report
- The bullous keratopathy market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Pfizer Inc
- Roche Ltd.
- Regeneron Pharmaceuticals
- Bayer AG
- Cellusion
- CRSTEurope
- Barraquer Eye Hospital
- Planchard Eye & Laser Center
- Medscape